Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM

Abstract Drug‐resistant tuberculosis (TB) is a major public health concern and contributes to high morbidity and mortality. New evidence supports the use of shorter duration, all‐oral regimens, which represent an encouraging treatment strategy for drug‐resistant TB. As a result, the landscape of drug‐resistant TB pharmacotherapy has drastically evolved regarding treatment principles and preferred agents. This narrative review focuses on the key updates of drug‐resistant TB treatment, including the use of short‐duration all‐oral regimens, while calling attention to current gaps in knowledge that may be addressed in future observational studies.